WO2026087510A2 - Compositions pharmaceutiques contenant des conjugués anticorps-médicaments stabilisés - Google Patents

Compositions pharmaceutiques contenant des conjugués anticorps-médicaments stabilisés

Info

Publication number
WO2026087510A2
WO2026087510A2 PCT/EP2025/080339 EP2025080339W WO2026087510A2 WO 2026087510 A2 WO2026087510 A2 WO 2026087510A2 EP 2025080339 W EP2025080339 W EP 2025080339W WO 2026087510 A2 WO2026087510 A2 WO 2026087510A2
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
pharmaceutical composition
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2025/080339
Other languages
English (en)
Inventor
Steffen WOELL
Carl-Oliver THIESS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of WO2026087510A2 publication Critical patent/WO2026087510A2/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des compositions pharmaceutiques stabilisées comprenant des conjugués anticorps-médicaments et des produits et des procédés associés, ainsi que lesdites compositions pharmaceutiques destinées à être utilisées en thérapie, par exemple comme thérapie anticancéreuse. L'invention concerne également l'utilisation de substances spécifiques pour stabiliser une composition pharmaceutique contenant un conjugué d'anticorps.
PCT/EP2025/080339 2024-10-21 2025-10-21 Compositions pharmaceutiques contenant des conjugués anticorps-médicaments stabilisés Pending WO2026087510A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP24207943.2 2024-10-21
EP24207943 2024-10-21

Publications (1)

Publication Number Publication Date
WO2026087510A2 true WO2026087510A2 (fr) 2026-04-30

Family

ID=93257584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/080339 Pending WO2026087510A2 (fr) 2024-10-21 2025-10-21 Compositions pharmaceutiques contenant des conjugués anticorps-médicaments stabilisés

Country Status (1)

Country Link
WO (1) WO2026087510A2 (fr)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2004010957A2 (fr) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
WO2008010101A2 (fr) 2006-07-18 2008-01-24 Sanofi-Aventis Anticorps antagoniste destiné au traitement du cancer
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
WO2022048883A1 (fr) 2020-09-04 2022-03-10 Merck Patent Gmbh Anticorps anti-ceacam5, conjugués et leurs utilisations

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6982321B2 (en) 1986-03-27 2006-01-03 Medical Research Council Altered antibodies
US5500362A (en) 1987-01-08 1996-03-19 Xoma Corporation Chimeric antibody with specificity to human B cell surface antigen
EP0404097A2 (fr) 1989-06-22 1990-12-27 BEHRINGWERKE Aktiengesellschaft Récepteurs mono- et oligovalents, bispécifiques et oligospécifiques, ainsi que leur production et application
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5821337A (en) 1991-06-14 1998-10-13 Genentech, Inc. Immunoglobulin variants
WO1993011161A1 (fr) 1991-11-25 1993-06-10 Enzon, Inc. Proteines multivalentes de fixation aux antigenes
US7087409B2 (en) 1997-12-05 2006-08-08 The Scripps Research Institute Humanization of murine antibody
WO2004010957A2 (fr) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
WO2008010101A2 (fr) 2006-07-18 2008-01-24 Sanofi-Aventis Anticorps antagoniste destiné au traitement du cancer
EP2050764A1 (fr) 2007-10-15 2009-04-22 sanofi-aventis Nouveau format d'anticorps bispécifique polyvalent
WO2022048883A1 (fr) 2020-09-04 2022-03-10 Merck Patent Gmbh Anticorps anti-ceacam5, conjugués et leurs utilisations

Non-Patent Citations (46)

* Cited by examiner, † Cited by third party
Title
"Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer", 2016, JOHN WILEY & SONS, INC.
"GenBank", Database accession no. AAA51967.1
"Precemtabart tocentecan", WHO DRUG INFORMATION, vol. 37, no. 4, 2023, pages 1137 - 1139
ALMAGROFRANSSON, FRONT BIOSCI., vol. 13, 2008, pages 1619 - 1633
BEHRENS ET AL., MOLECULAR PHARMACEUTICS, vol. 12, no. 11, 2015, pages 3986 - 3998
BOERNER ET AL., J. IMMUNOL., vol. 147, no. 1, 1991, pages 86 - 95
CHAU, LANCET, vol. 394, no. 10200, 2019, pages 793 - 804
COCKRELL GM ET AL., MOL PHARM., vol. 12, no. 6, 1 June 2015 (2015-06-01), pages 6
COCKRELL GM ET AL.: "Photoinduced aggregation of a model antibody-drug conjugate", MOL PHARM., vol. 12, no. 6, 1 June 2015 (2015-06-01), pages 1784 - 97
COLE ET AL.: "Monoclonal Antibodies and Cancer Therapy", 1985, ALAN R. LISS INC., pages: 77 - 96
DICKGIESSER ET AL., BIOCONJUGATE CHEM., vol. 31, no. 4, 2020, pages 1070 - 1076
DICKGIESSER ET AL., METHODS IN MOLECULAR BIOLOGY: ENZYME-MEDIATED LIGATION METHODS, vol. 2012, 2019, pages 135 - 149
F. JOHANN ET AL.: "Miniaturized forced degradation of therapeutic proteins and ADCs by agitation-induced aggregation using orbital shaking of microplates", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 111, no. 5, 2022, pages 1401 - 1413
FEI ET AL., JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, vol. 14, no. 3, 2018, pages 405 - 429
GAZZANO-SANTORO ET AL., JOURNAL OF IMMUNOLOGICAL METHODS., vol. 202, no. 2, March 1997 (1997-03-01), pages 163 - 171
GORKA ET AL., ACCOUNTS OF CHEMICAL RESEARCH, vol. 51, no. 12, 2018, pages 3226 - 3235
GROMEK ET AL., CURRENT TOPICS IN MEDICINAL CHEMISTRY, vol. 14, no. 24, 2014, pages 2822 - 2834
HARRIS, BIOCHEM. SOC. TRANSACTIONS, vol. 23, 1995, pages 1035 - 1038
HERMANSON G. T: "Bioconjugate Techniques", 1996, ACADEMIC PRESS, pages: 234 - 242
HEWITT ET AL., J CHROMATOGR A, vol. 1215, no. 1-2, 26 December 2008 (2008-12-26), pages 156 - 60
HOLLINGER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HOOGENBOOMWINTER, J. MOL. BIOL., vol. 222, 1991, pages 581
HURLEGROSS, CURR. OP. BIOTECH., vol. 5, 1994, pages 428 - 433
JESPERS ET AL., BIOTECHNOLOGY, vol. 113, 1994, pages 899 - 315
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KOHLERMILSTEIN, EUR. J. IMMUNOL., vol. 5, 1976, pages 511 - 519
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 27, no. 1, 2003, pages 55 - 77
LI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 103, 2006, pages 3557 - 3562
LOEW ET AL.: "Analytical Protein A Chromatography as a Quantitative Tool for the Screening of Methionine Oxidation in Monoclonal Antibodies", J PHARM SCI., vol. 101, no. 11, 2012, pages 4248 - 57
MORRISON ET AL., PROC. NATL. ACAD. SCI USA, vol. 81, 1984, pages 6851 - 6855
NEEDLEMANWUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
NICOLAOU ET AL., ACCOUNTS OF CHEMICAL RESEARCH, vol. 52, no. 1, 2019, pages 127 - 139
NIMOY, PHARMACEUTICALS, vol. 11, 2018
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ROHRER: "Process Scale Purification of Antibodies", 2017, JOHN WILEY & SONS, INC., pages: 595 - 614
STEFANO, METHODS IN MOLECULAR BIOLOGY, vol. 1045, 2013, pages 145 - 171
STROOP SD ET AL.: "Photosensitizers form in histidine buffer and mediate the photodegradation of a monoclonal antibody", J PHARM SCI., vol. 100, no. 12, December 2011 (2011-12-01), pages 5142 - 55
SUMITRA A ET AL., PHARMACEUTICAL GLASS INTERACTIONS: A REVIEW OF POSSIBILITIES
SUMITRA A. PILLAI ET AL., J. PHARM. SCI. & RES., vol. 8, no. 2, 2016, pages 103 - 111
TIBERGHIEN ET AL., JOURNAL OF ORGANIC CHEMISTRY, vol. 84, no. 8, 2019, pages 4830 - 4836
TOADER: "Cancer II", TOPICS IN MEDICINAL CHEMISTRY, vol. 28, 2018, pages 289 - 332
VAKLAVASFORERO, METHODS IN MOLECULAR BIOLOGY, vol. 899, 2012, pages 489 - 497
VAN DIJKVAN DE WINKEL, CURR. OPIN. PHARMACOL., vol. 5, 2001, pages 368 - 374
VASWANIHAMILTON, ANN. ALLERGY, ASTHMA & IMMUNOL., vol. 1, 1998, pages 105 - 115
WHO DRUG INFORMATION, vol. 37, no. 4, 2023, pages 1137 - 1139

Similar Documents

Publication Publication Date Title
EP4208481B1 (fr) Anticorps contre ceacam5, leurs conjugués et leurs modes d'utilisation
JP7383682B2 (ja) 抗ｅｄｂ抗体および抗体－薬物コンジュゲート
CN108348608B (zh) 抗5t4抗体和抗体-药物缀合物
JP2022513684A (ja) 抗１９１ｐ４ｄ１２抗体薬物コンジュゲートを含む薬学的組成物、およびその使用方法
JP2026048848A (ja) １９１ｐ４ｄ１２タンパク質に結合する抗体薬物コンジュゲート（ａｄｃ）による癌の治療方法
CN119487076A (zh) 抗ceacam5抗体及其缀合物和用途
KR20240099178A (ko) 항 cd37 항체-약물 콘주게이트
CN118852442A (zh) 抗ptk7抗体及其用途
CN117999101A (zh) 靶向EGFR的Fc抗原结合片段-药物缀合物
CN120988123B (zh) 一种抗人NaPi2b的人源化单克隆抗体及其应用
IL282913B2 (en) Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
HK40092426A (zh) 抗-edb抗体和抗体-药物缀合物
CN121794298A (zh) 抗ror1抗体及其用途
WO2025242845A1 (fr) Traitement du cancer colorectal
BR112019007760B1 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica, ácido nucleico, vetor, processo para a produção do conjugado de anticorpofármaco e uso do conjugado de anticorpo-fármaco
HK40061011B (en) Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
HK40061011A (en) Filterable duocarmycin-containing antibody-drug conjugate compositions and related methods
BR122024006481A2 (pt) Conjugados de anticorpo-fármaco, composição farmacêutica e seus usos, processo para a produção de um conjugado de anticorpo-fármaco, anticorpo, polinucleotídeo, vetor, célula hospedeira, método para produzir o anticorpo e método para detectar domínio b extra de fibronectina